Steven A. Akman

Dr. Steven A. Akman

Hematology Oncology | Oncology
86 Jonathan Lucas St, 2nd Floor, 3rd Floor, 
Charleston, SC 
Accepting New Patients
Offers Telehealth
86 Jonathan Lucas St, 2nd Floor, 3rd Floor, 
Charleston, SC 

Overview

Dr. Steven Akman has been practicing hematology-oncology for more than 43 years. During his long career, he has taken care of patients with a range of non-malignant hematologic conditions, malignant hematologic conditions, and solid tumors. His area of emphasis has been in the medical oncologic management of breast cancer. He directed the Breast Cancer Center of Excellence of the Wake Forest University Comprehensive Cancer Center for 17 years.His wealth of experience allows him to bring maturity, patience, insight, and empathy to every patient interaction. He plans to spend the next five years taking care of hematology/oncology patients in the outpatient setting. His goal is to provide every patient with the highest possible quality of care and the educational and emotional support required for an effective partnership. Providing the highest possible quality of care includes the opportunity to provide access to clinical trials.

His clinical expertise encompasses Thrombocytopenia, Breast Cancer, Lung Cancer, and Iron Deficiency Anemia.

He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 27 clinical trials. Dr. Akman is currently accepting new patients.

Specialties

Hematology Oncology
Oncology

Licenses

Internal Medicine in NC

Hospital Affiliations

Colleton Medical Center
Musc Medical Center
Hampton Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

MUSC Health Hematology Oncology at Hollings Cancer Center
86 Jonathan Lucas St, 2nd Floor, 3rd Floor, Charleston, SC 29425

Additional Areas of Focus

Dr. Akman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Breast Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

26 Clinical Trials

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: August 10, 2026
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
View 9 Less Clinical Trials

11 Total Publications

A G-quadruplex DNA-affinity Approach for Purification of Enzymatically Active G4 Resolvase1.
A G-quadruplex DNA-affinity Approach for Purification of Enzymatically Active G4 Resolvase1.
Journal: Journal of visualized experiments : JoVE
Published: April 01, 2017
Similar Doctors
Expertise in
17
conditions
Dr. Thai H. Ho
Hematology Oncology | Oncology
Expertise in
17
conditions
Dr. Thai H. Ho
Hematology Oncology | Oncology
Referral may be required

MUSC Health Hematology Oncology At Hollings Cancer Center

86 Jonathan Lucas St, 2nd Floor, 3rd Floor, 
Charleston, SC 
 (0.1 miles away)
843-792-9300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Thai Ho has been caring for patients affected by genitourinary cancers for over 10 years. His area of expertise and the focus of his research is in treating kidney and bladder cancers. He also sees patients with kidney, bladder, upper tract urothelial, and prostate cancers, as well as patients affected by hereditary cancer syndromes. Dr. Ho completed the Baylor College of Medicine Physician Scientist Program in 2006, internal medicine residency at Washington University in St. Louis in 2009, and Medical Oncology Fellowship at MD Anderson Cancer Center in 2012.Dr. Ho's research is funded by the National Institutes of Health and Department of Defense to better match cancer patients with targeted therapies by using precision medicine approaches to identify a cancer's unique vulnerabilities. At MUSC Hollings Cancer Center, Dr. Ho is the Director of Precision Medicine and an Associate Professor in the Division of Hematology \& Oncology. Prior to joining MUSC, Dr. Ho was an Associate Professor faculty the Mayo Clinic where he was a member of the Center for Individualized Medicine Epigenomics Group, Genomic Tumor Board, and von Hippel-Lindau Clinic. Dr. Ho is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Nephrectomy, and Orchiectomy. Dr. Ho is currently accepting new patients.

Expertise in
40
conditions
Expertise in
40
conditions
Referral may be required

Complementary Cancer Care Inc.

86 Jonathan Lucas St, 
Charleston, SC 
 (0.1 miles away)
843-792-9300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Hawkins is an Oncologist practicing medicine in Charleston, South Carolina. Dr. Hawkins is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Hawkins is currently accepting new patients.

Expertise in
36
conditions
Expertise in
36
conditions
Referral may be required

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (0.2 miles away)
843-792-2300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Lindhorst is an Oncologist practicing medicine in Charleston, South Carolina. Dr. Lindhorst is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Awake Craniotomy. Dr. Lindhorst is currently accepting new patients.

Frequently Asked Questions about Dr. Steven A. Akman

How do I make an appointment with Dr. Steven A. Akman?

You can book an appointment with Dr. Steven A. Akman by calling their office at 843-792-9300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Steven A. Akman a top-rated expert for Thrombocytopenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Steven A. Akman is classified as an Experienced expert for Thrombocytopenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Steven A. Akman specialize in?

While Dr. Steven A. Akman is a Hematology Oncology, they have specific expertise in Thrombocytopenia, Breast Cancer, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Steven A. Akman participate in research or clinical trials?

Yes. Dr. Steven A. Akman has published 11 articles and abstracts on conditions like Thrombocytopenia. You can view a list of Dr. Steven A. Akman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Steven A. Akman accept my insurance?

Dr. Steven A. Akman accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 843-792-9300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Akman's expertise for a condition
ConditionClose
        View All 40 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile